Clinical Trial Update: Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety and tolerability of toripalimab in patients with advanced solid tumors, including melanoma and urothelial cancer, has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Urothelial Cancer

Drugs mentioned

• Toripalimab (Toripalimab)

Snippet

Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Conditions: Melanoma, Urological Cancer | Phase 1 | Status: COMPLETED